Canakinumab Cuts Secondary CV Events in Phase 3 CANTOS

Top-line results show the monoclonal antibody, given on top of standard care, significantly reduced the risk of cardiovascular death, nonfatal MI, and nonfatal stroke in patients with a prior MI and elevated CRP.